Huang Tao, Yi Dandan, Xu Lei, Bu Erlan, Zhu Chengyan, Sang Jianfeng, Zhang Yifen
Department of Thyroid and Breast, Lianyungang First People's Hospital Lianyungang, Jiangsu Province, China.
Department of General Surgery, Nanjing Drum Tower Hospital Nanjing, Jiangsu Province, China.
Int J Clin Exp Pathol. 2017 Dec 1;10(12):11610-11616. eCollection 2017.
Circulating microRNAs (miRNAs) are potential biomarkers for papillary thyroid carcinoma (PTC). The aim of this study was to evaluate the diagnostic and prognostic value of serum miR-381 in PTC. A total of 87 patients with PTC, 50 cases with benign thyroid nodules (BTN) and 50 healthy volunteers were enrolled. The expression levels of serum miR-381 were measured using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The results indicated that serum miR-381 expression was significantly decreased in PTC patients compared to that of BTN patients or healthy controls. Moreover, serum miR-381 showed good performance to differentiate PTC cases from controls. Next, reduced serum miR-381 expression was positively correlated with aggressive clinical features and shorter overall survival. Furthermore, serum miR-381 levels were greatly elevated in 21 patients with advanced-stage (stage III/IV) PTC after surgery. Finally, univariate and multivariate Cox regression analysis confirmed that miR-381 in serum was an independent prognostic indicator for OS in PTC patients. Collectively, serum miR-381 might serve as a non-invasive biomarker for the diagnosis and prognosis of PTC.
循环微RNA(miRNA)是甲状腺乳头状癌(PTC)的潜在生物标志物。本研究旨在评估血清miR-381在PTC中的诊断和预后价值。共纳入87例PTC患者、50例良性甲状腺结节(BTN)患者和50名健康志愿者。采用定量逆转录-聚合酶链反应(qRT-PCR)检测血清miR-381的表达水平。结果表明,与BTN患者或健康对照相比,PTC患者血清miR-381表达显著降低。此外,血清miR-381在区分PTC病例与对照方面表现良好。其次,血清miR-381表达降低与侵袭性临床特征和较短的总生存期呈正相关。此外,21例晚期(III/IV期)PTC患者术后血清miR-381水平大幅升高。最后,单因素和多因素Cox回归分析证实,血清miR-381是PTC患者总生存期的独立预后指标。总体而言,血清miR-381可能作为PTC诊断和预后的非侵入性生物标志物。